Post by Taylor Wessing UK

A team led by Ross McNaughton and Oli Denne has advised Infinitopes, an Oxford-based clinical-stage cancer vaccine biotechnology company, on its seed finance extension taking its seed round to $35 million: https://lnkd.in/e37rN8Xv The funding will support the launch of Infinitopes' first-in-human clinical trial of ITOP1, its precision therapeutic vaccine aimed at preventing recurrence in oesophageal cancer. #Corporate #LifeSciences #BioTech